Notable News

Published 10/18/2022 Link to: https://www.pharmatechoutlook.com/notable-labs

Published 9/25/2022 In support of the MDS Foundation, Notable Labs took part in the “Move for MDS Walk”, a 5-cities event that brings together patients, family members and caregivers in the MDS community. Matt de Silva, Notable’s Founder and Executive Chairman, joined the event from Chicago, IL at Maggie Daley Park on September 25, 2022. […]

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology. Meagan Parrish, Lead Editor PharmaVoice Published May 2, 2022 – Many pharma execs find that a personal experience with a patient serves as a catalyst to enter the field. For Dr. Thomas Bock, CEO of […]

FOSTER CITY, CA – Dec 3, 2020 – Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, will present at the 2020 Virtual ASH Annual Meeting an update to the recently published article in Blood Advances.

FOSTER CITY, CA and SEATTLE; Oct. 28, 2020 (Business Wire) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership.

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

FOSTER CITY, CA – Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

FOSTER CITY, CA – Aug. 06, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anti-cancer therapies.

FOSTER CITY, CA – July 08, 2020 (GLOBE NEWSWIRE) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that Joseph Wagner, PhD, has joined the company as Chief Scientific Officer. Dr. Wagner.